Cargando…

Pharmacodynamic effects of daclizumab in the intrathecal compartment

OBJECTIVE: It was previously demonstrated that daclizumab therapy normalizes cellular cerebrospinal fluid (CSF) abnormalities typical of multiple sclerosis (MS) in the majority of treated patients. However, CSF cells represent only the mobile portion of intrathecal immune responses. Therefore, we as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Komori, Mika, Kosa, Peter, Stein, Jason, Zhao, Vivian, Blake, Andrew, Cherup, Jamie, Sheridan, James, Wu, Tianxia, Bielekova, Bibiana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497534/ https://www.ncbi.nlm.nih.gov/pubmed/28695148 http://dx.doi.org/10.1002/acn3.427

Ejemplares similares

Daclizumab reverses intrathecal immune cell abnormalities in multiple sclerosis
por: Lin, Yen Chih, et al.
Publicado: (2015)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination
por: Lin, Yen Chih, et al.
Publicado: (2016)

Cerebrospinal Fluid IL-12p40, CXCL13 and IL-8 as a Combinatorial Biomarker of Active Intrathecal Inflammation
por: Bielekova, Bibiana, et al.
Publicado: (2012)

Intrathecal B Cells in MS Have Significantly Greater Lymphangiogenic Potential Compared to B Cells Derived From Non-MS Subjects
por: Stein, Jason, et al.
Publicado: (2018)

Idebenone does not inhibit disability progression in primary progressive MS
por: Kosa, Peter, et al.
Publicado: (2020)

Pioglitazone regulates myelin phagocytosis and multiple sclerosis monocytes
por: Natrajan, Muktha S., et al.
Publicado: (2015)

Intrathecal, Not Systemic Inflammation Is Correlated With Multiple Sclerosis Severity, Especially in Progressive Multiple Sclerosis
por: Milstein, Joshua L., et al.
Publicado: (2019)

Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
por: Masvekar, Ruturaj, et al.
Publicado: (2021)

CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS
por: Elkins, J., et al.
Publicado: (2015)

Finger and foot tapping as alternative outcomes of upper and lower extremity function in multiple sclerosis
por: Tanigawa, Makoto, et al.
Publicado: (2017)

A vital role for IL-2 trans-presentation in DC-mediated T cell activation in humans as revealed by daclizumab therapy
por: Wuest, Simone C., et al.
Publicado: (2011)

Enhancing the clinical value of serum neurofilament light chain measurement
por: Kosa, Peter, et al.
Publicado: (2022)

Confounder-adjusted MRI-based predictors of multiple sclerosis disability
por: Kim, Yujin, et al.
Publicado: (2022)

1820. Efficacy of Pulse-Taper Corticosteroid Adjunctive Therapy for Refractory Non-HIV Cryptococcal Meningoencephalitis
por: Anjum, Seher, et al.
Publicado: (2019)

Extensive Healthy Donor Age/Gender Adjustments and Propensity Score Matching Reveal Physiology of Multiple Sclerosis Through Immunophenotyping
por: Hannikainen, Paavali A., et al.
Publicado: (2020)

Development of a Sensitive Outcome for Economical Drug Screening for Progressive Multiple Sclerosis Treatment
por: Kosa, Peter, et al.
Publicado: (2016)

Spotlight on daclizumab: its potential in the treatment of multiple sclerosis
por: Milo, Ron, et al.
Publicado: (2016)

Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry
por: Ranganath, Thanmayi, et al.
Publicado: (2020)

NeurEx: digitalized neurological examination offers a novel high‐resolution disability scale
por: Kosa, Peter, et al.
Publicado: (2018)

Smartphone-based symbol-digit modalities test reliably captures brain damage in multiple sclerosis
por: Pham, Linh, et al.
Publicado: (2021)

New Multiple Sclerosis Disease Severity Scale Predicts Future Accumulation of Disability
por: Weideman, Ann Marie, et al.
Publicado: (2017)

Machine learning-optimized Combinatorial MRI scale (COMRISv2) correlates highly with cognitive and physical disability scales in Multiple Sclerosis patients
por: Kelly, Erin, et al.
Publicado: (2022)

Assessment of Smartphone-Based Spiral Tracing in Multiple Sclerosis Reveals Intra-Individual Reproducibility as a Major Determinant of the Clinical Utility of the Digital Test
por: Messan, Komi S., et al.
Publicado: (2022)

Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms
por: Kosa, Peter, et al.
Publicado: (2022)

Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study Program
por: Gold, Ralf, et al.
Publicado: (2016)

Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosis
por: Cohan, Stanley
Publicado: (2016)

Drug reaction with eosinophilia and systemic symptoms after daclizumab therapy in MS
por: Scheibe, Franziska, et al.
Publicado: (2018)

Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
por: Panackal, Anil A., et al.
Publicado: (2015)

Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
por: Reardon, Jennifer, et al.
Publicado: (2013)

GFAPα IgG-associated encephalitis upon daclizumab treatment of MS
por: Luessi, Felix, et al.
Publicado: (2018)

A fatal case of daclizumab-induced liver failure in a patient with MS
por: Stettner, Mark, et al.
Publicado: (2019)

Management of MS Patients Treated With Daclizumab – a Case Series of 267 Patients
por: Rommer, Paulus S., et al.
Publicado: (2020)

DRESS Syndrome and Daclizumab Failure—Were Potentially Dangerous Signs Missed in Clinical Trials?
por: Avasarala, Jagannadha
Publicado: (2018)

Bortezomib for anti-NMDAR encephalitis following daclizumab treatment in a patient with multiple sclerosis
por: Karunaratne, Kushan, et al.
Publicado: (2021)

Identifying and Quantifying Neurological Disability via Smartphone
por: Boukhvalova, Alexandra K., et al.
Publicado: (2018)

Smartphone Level Test Measures Disability in Several Neurological Domains for Patients With Multiple Sclerosis
por: Boukhvalova, Alexandra K., et al.
Publicado: (2019)

Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
por: Sageshima, Junichiro, et al.
Publicado: (2009)

A randomized controlled trial of daclizumab versus anti-thymocyte globulin induction for heart transplantation
por: Mullen, John C, et al.
Publicado: (2014)

Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis
por: Giovannoni, Gavin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ipon9ahc1bsvpd11psegklkabq